Please use this identifier to cite or link to this item:
|Title:||PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells|
Biological applications of polymers
Drug delivery systems
|Citation:||Tan, L., Neoh, K.G., Kang, E.-T., Choe, W.S., Su, X. (2011-10-10). PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromolecular Bioscience 11 (10) : 1331-1335. ScholarBank@NUS Repository. https://doi.org/10.1002/mabi.201100173|
|Abstract:||Targeted drug delivery is especially important in cancer treatment as many anti-cancer drugs are non-specific and highly toxic to both cancer and normal cells. The targeted drug delivery of DOX to the MUC1-expressing breast cancer cell line (MCF7) was obtained using APT as a carrier. Modification of the APT-DOX complex by PEG increases the survivability of the macrophage control (RAW 264.7) by about six-fold as compared to free DOX treatment without significantly affecting the cytotoxicity toward the target cell line. Thus, PEG-APT-DOX is potentially a new therapeutic agent for targeted drug delivery to MUC1-expressing cell lines. © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.|
|Source Title:||Macromolecular Bioscience|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 19, 2018
WEB OF SCIENCETM
checked on Jul 3, 2018
checked on Jun 29, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.